/PRNewswire/ Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and.
/PRNewswire/ The "Global Genetic Disorders Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com s.